Previous close | 169.54 |
Open | 168.59 |
Bid | 165.87 x 800 |
Ask | 168.48 x 800 |
Day's range | 166.74 - 169.11 |
52-week range | 130.96 - 182.89 |
Volume | |
Avg. volume | 5,617,229 |
Market cap | 297.115B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 61.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 6.20 (3.69%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.